Meeting
2022 ASCO Annual Meeting
Neoadjuvant nivolumab with or without IDO inhibitor in head and neck squamous cell carcinoma (HNSCC): Final pathologic and clinical outcomes.
Authors
Adam Luginbuhl
Department of Otolaryngology, Thomas Jefferson University, Philadelphia, PA
Adam Luginbuhl , Jennifer Maria Johnson , Elizabeth R Scott , Larry Harshyne , Elizaveta Flerova Flerova , Madalina Tuluc , Stacey Gargano , Benjamin Leiby , Matthew O. Old , Nolan Seim , Joseph M. Curry , David M. Cognetti , Athanassios Argiris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03854032
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6070)
DOI
10.1200/JCO.2022.40.16_suppl.6070
Abstract #
6070
Poster Bd #
62
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer.
First Author: Ralph Zinner
Poster
2024 ASCO Annual Meeting
Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): An open-label, single-arm, phase 2 study.
First Author: Zhigong Wei
Poster
2023 ASCO Annual Meeting
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
First Author: Robert L. Ferris
Poster
2022 ASCO Annual Meeting
Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.
First Author: Yara L. Verschoor